This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Albireo Pharma Croissance future
Future contrôle des critères 2/6
Informations clés
62.9%
Taux de croissance des bénéfices
61.4%
Taux de croissance du BPA
| Biotechs croissance des bénéfices | 27.9% |
| Taux de croissance des recettes | 51.1% |
| Rendement futur des capitaux propres | n/a |
| Couverture par les analystes | Good |
| Dernière mise à jour | 24 Feb 2023 |
Mises à jour récentes de la croissance future
Recent updates
We're Hopeful That Albireo Pharma (NASDAQ:ALBO) Will Use Its Cash Wisely
Jan 02
Rock star Growth Puts Albireo Pharma (NASDAQ:ALBO) In A Position To Use Debt
Oct 25Albireo Pharma achieves positive phase 3 top-line results of Bylvay in Alagille syndrome
Oct 11Albireo Pharma: Assessing The Sagard Deal
Oct 03Albireo gains on royalty agreement for pruritus therapy
Sep 22Albireo gets reimbursed access to liver disease drug Bylvay in Italy
Sep 06These Analysts Just Made A Significant Downgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) EPS Forecasts
Aug 23Albireo Pharma GAAP EPS of -$2.04, revenue of $8.2M
Aug 15Albireo: The Commercialization Of Bylvay Is The Key To A Fair Valuation
Jul 22Despite Lacking Profits Albireo Pharma (NASDAQ:ALBO) Seems To Be On Top Of Its Debt
May 10Albireo: A Speculative Play With Upside
May 03Is Albireo Pharma (NASDAQ:ALBO) Using Debt Sensibly?
Feb 02Albireo: Successful And Accelerating Global Launch Drives Sales Revenue
Jan 31Albireo: Reasons For A Successful Transformation Into A Commercial Company
Nov 24Albireo Pharma: A Post Approval Assessment
Aug 09Albireo reports expanded data on Bylvay and A3907 at EASL international liver congress
Jun 21Some Shareholders May find It Hard To Increase Albireo Pharma, Inc.'s (NASDAQ:ALBO) CEO Compensation This Year
Jun 11Why Albireo Must Be Valued Higher Than Its Competitor Based On The Value Of Odevixibat
Apr 26Industry Analysts Just Made A Substantial Upgrade To Their Albireo Pharma, Inc. (NASDAQ:ALBO) Revenue Forecasts
Feb 27Albireo launches late-stage trial of odevixibat in Alagille Syndrome
Dec 17Albireo submits U.S. and European applications for odevixibat in liver disease
Dec 09Albireo Pharma (ALBO) Investor Presentation - Slideshow
Nov 17Albireo Pharma's odevixibat shows durable response in a rare pediatric liver disease
Nov 13Prévisions de croissance des bénéfices et des revenus
| Date | Recettes | Les revenus | Flux de trésorerie disponible | Cash from Op | Moy. Nombre d'analystes |
|---|---|---|---|---|---|
| 12/31/2025 | 248 | -5 | N/A | N/A | 5 |
| 12/31/2024 | 128 | -102 | N/A | N/A | 5 |
| 12/31/2023 | 61 | -144 | N/A | N/A | 7 |
| 12/31/2022 | 35 | -159 | N/A | N/A | 7 |
| 9/30/2022 | 57 | -131 | -116 | -115 | N/A |
| 6/30/2022 | 51 | -36 | -114 | -113 | N/A |
| 3/31/2022 | 45 | -33 | -109 | -108 | N/A |
| 12/31/2021 | 41 | -34 | -108 | -108 | N/A |
| 9/30/2021 | 11 | -48 | -122 | -122 | N/A |
| 6/30/2021 | 9 | -136 | -121 | -120 | N/A |
| 3/31/2021 | 9 | -120 | -112 | -112 | N/A |
| 12/31/2020 | 8 | -108 | -101 | -101 | N/A |
| 9/30/2020 | 12 | -90 | -85 | -85 | N/A |
| 6/30/2020 | 11 | -82 | -73 | -73 | N/A |
| 3/31/2020 | 11 | -78 | -64 | -63 | N/A |
| 12/31/2019 | 10 | -63 | -53 | -53 | N/A |
| 9/30/2019 | 4 | -71 | -51 | -51 | N/A |
| 6/30/2019 | 3 | -63 | -47 | -47 | N/A |
| 3/31/2019 | 2 | -61 | -41 | -41 | N/A |
| 12/31/2018 | 13 | -46 | -27 | -27 | N/A |
| 9/30/2018 | 12 | -35 | -25 | -25 | N/A |
| 6/30/2018 | 12 | -28 | -20 | -20 | N/A |
| 3/31/2018 | 11 | -19 | -18 | -18 | N/A |
| 12/31/2017 | 0 | -24 | -28 | -28 | N/A |
| 9/30/2017 | 3 | -31 | -26 | -26 | N/A |
| 6/30/2017 | 3 | -28 | -25 | -25 | N/A |
| 3/31/2017 | 11 | -20 | -15 | -15 | N/A |
| 12/31/2016 | 11 | -16 | -9 | -9 | N/A |
| 9/30/2016 | 13 | -5 | -1 | -1 | N/A |
| 6/30/2016 | 13 | -4 | N/A | 1 | N/A |
| 3/31/2016 | 5 | -8 | N/A | -5 | N/A |
Prévisions de croissance des analystes
Taux de revenus par rapport au taux d'épargne: ALBO is forecast to remain unprofitable over the next 3 years.
Bénéfices vs marché: ALBO is forecast to remain unprofitable over the next 3 years.
Croissance élevée des bénéfices: ALBO is forecast to remain unprofitable over the next 3 years.
Chiffre d'affaires vs marché: ALBO's revenue (51.1% per year) is forecast to grow faster than the US market (6.9% per year).
Croissance élevée des revenus: ALBO's revenue (51.1% per year) is forecast to grow faster than 20% per year.
Prévisions de croissance du bénéfice par action
Rendement futur des capitaux propres
ROE futur: Insufficient data to determine if ALBO's Return on Equity is forecast to be high in 3 years time